Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

References for PMC Articles for PubMed (Select 21575868)

1.

Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.

Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR Jr, Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):239-46. doi: 10.1016/j.jalz.2010.03.006. Review.

2.

The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.

Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, Price JC, Reiman EM, Skovronsky D, Koeppe RA; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):221-9. doi: 10.1016/j.jalz.2010.03.003.

3.

Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.

Jack CR Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, Schuff N, Krueger G, Killiany RJ, Decarli CS, Dale AM, Carmichael OW, Tosun D, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):212-20. doi: 10.1016/j.jalz.2010.03.004. Review.

4.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M.

Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.

PMID:
20189881
5.

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M; Bapineuzumab 201 Clinical Trial Investigators.

Neurology. 2009 Dec 15;73(24):2061-70. doi: 10.1212/WNL.0b013e3181c67808. Epub 2009 Nov 18.

6.

Alzheimer's disease therapeutic research: the path forward.

Aisen PS.

Alzheimers Res Ther. 2009 Jul 9;1(1):2. doi: 10.1186/alzrt2.

7.

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.

Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM.

Ann Neurol. 2009 Jul;66(1):48-54. doi: 10.1002/ana.21623.

8.

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.

Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D.

Neurology. 2006 Nov 28;67(10):1757-63. Epub 2006 Nov 2.

PMID:
17082468
9.

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.

Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM.

Nat Med. 2006 Jul;12(7):856-61. Epub 2006 Jun 25.

10.

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792(QS-21)-201 Study.

Neurology. 2005 May 10;64(9):1563-72.

PMID:
15883317
11.

A pilot study of prednisone in Alzheimer's disease.

Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Ryan T, Davis KL.

Dementia. 1996 Jul-Aug;7(4):201-6.

PMID:
8835883
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk